BioSpace News Archive

Patisiran Demonstrated Improvement of Cardiomyopathy in Prospectively Defined Subgroup of Patients with Cardiac Amyloid Involvement, Relative to Placebo.

Walgreens Boots Alliance, Inc. announced financial results for the second quarter of fiscal 2018, which ended 28 February 2018.

Laboratory network standardizes on common NGS platform to efficiently profile patient samples across multiple cancer centers

PharmaCord LLC, a rapidly growing patient services company that provides customized solutions to the biopharmaceutical industry, has announced the appointment of Patrick Lee as vice president of strategy.

Ipsen announced that the European Medicines Agency (EMA), the European regulatory authority, has validated the filing of a new application for an additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).

Exelixis, Inc. announced that its partner Ipsen received validation of the application for variation to the CABOMETYX® (cabozantinib) marketing authorization from the European Medicines Agency (EMA) for the addition of a new indication for patients with previously treated advanced hepatocellular carcinoma (HCC).

Evotec AG reported financial results and corporate updates for the fiscal year ended 31 December 2017.

Owlstone Medical announced the launch of its Breath Biopsy® Kits, based on the company’s proprietary Breath Biopsy platform.

GB Sciences, Inc. is extremely pleased to announce it has signed a letter of intent to purchase 100% of the ownership interests of NevadaPURE’s Las Vegas operation for $28 million in cash and the assumption of approximately $5 million of outstanding liabilities.

The paper identified digital biomarkers that could predict performance on gold-standard neurocognitive tests.